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Abstract
OBJECTIVE: To study the possible roles of Jinlong
capsule (JLC) on the proliferation and apoptosis of
human pancreatic cancer cells BxPC-3.
METHODS: The human pancreatic cancer cells Bx-
PC-3 were treated with JLC at the concentration of
0.05-1.00 mg/mL for 24-120 h. The inhibition rate of
JLC on human pancreatic cancer cells BxPC-3 was
detected by 3-(4,5-dimethiylthiazol-2-yl)-2, 5-diphe-
nyl tetrazolium bromide (MTT) assay. Flow cytome-
try was employed to measure cell apoptosis using
Annexin V-FITC/Propidium iodide (AV-FITC/PI)
method. Cell cycles were determined by PI staining.
The expression of S100 Calcium binding protein A4
(S100A4) in cell matrix was measured by en-
zyme-linked immunosorbent assay (ELISA). The ex-
pression levels of apoptosis-related protein such as
BCL2/adenovirus E1B 19 kDa interacting protein 3
(BNIP3), B-cell lymphoma/leukemia-2 (Bcl-2) and
Cys-teinylaspartate specific proteinase 3 (Cas-
pase-3) were detected byWestern blotting.
RESULTS: JLC significantly inhibited the prolifera-
tion of human pancreatic cancer cells BxPC-3 in a
dose-dependent and time-dependent manner. JLC
promoted cell apoptosis and maintained cell cycle
in S and G2/M phase rather than G1/G0 phase. The
expression of S100A4 in the cell matrix was re-
duced. The expression of cell apoptotic protein
BNIP3 was increased while Bcl-2 was decreased.
CONCLUSION: JLC can inhibit the proliferation of
human pancreatic cancer cells BxPC-3 by stimulat-
ing cell apoptosis, arresting the cell cycle at S and
G2/M phase which blocks the circulation of normal
cell cycle and reducing the expression of S100A4
protein. Higher pro-apoptosis protein BNIP3 and
lower anti-apoptosis protein Bcl-2 levels were
found, which may be related to the apoptotic ef-
fects of JLC.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
Pancreatic cancer is a malignant solid tumor grown in
internal organs, one of the hardest cancer which can be
early diagnosed and treated. Five-year survival of pan-
creatic cancer is about 5%.1 The morbidity and mortali-
ty of pancreatic cancer lead to the belief that pancreatic
cancer is "the king of the cancer" in the 21st century.
In order to improve the survival rate of patients with
pancreatic cancers, the development of new effective
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treatment strategies and new medicines to treat pancre-
atic cancer is of great importance.
Jinlong capsule (JLC), composed of Xianbaihuashe
(Fresh Bungarus), Xianjinshe (Fresh Agkistrodon), Xian-
shougong (Fresh Gecko), etc, is a Traditional Chinese
Medicine preparation. The active ingredients are ex-
tracted by the process of modern cryogenic and bio-
chemical separation from raw animal drugs. The data
of our previous studies has revealed that JLC is
multi-targeted on tumors inhibition.2-5 However, its
role on the inhibition of pancreatic cancer has not
been reported yet. In this study, we performed experi-
ments to explore how JLC influences the proliferation
and apoptosis of human pancreatic cancer cells Bx-
PC-3 and possible mechanism involved. The results
will support the fundamental roles of JLC on pancreat-
ic cancer treatment and pave the way for further stud-
ies.
MATERIALS ANDMETHODS
Cell line
Human pancreatic cancer cells BxPC-3 were purchased
from Shanghai institute of biochemistry and cell biolo-
gy, Chinese Academy of Sciences (Shanghai, China).
Reagents and instruments
Dulbecco's modified eagle medium (DMEM) was the
product of HyClone Laboratories, Inc. (Utah, USA),
containing 15% fetal calf serum, 1% penicillin and
streptomycin in the experiment. Fetal calf serum was
from Sijiqing Company (Hangzhou, China), and was
inactivated for 30 min at 56℃ . JLC was purchased
from Jiansheng Pharmaceutical Co., Ltd. (No.
110425, Beijing, China). The JLC powder was dis-
solved in the culture medium to configure the stock so-
lution in 4 mg/mL, which was diluted to the desired
concentration in the experiment. Gemcitabine hydro-
chloride (GEM) of 200 mg/ampoule was from Hansoh
Pharmaceutical Co., Ltd. (Jiangsu, China). Anecxin-V/
PI apoptosis kit and cell cycle staining solution were
purchased from Biovision, Inc. (California, USA). Hu-
man S100 Calcium binding protein A4 (S100A4) ELI-
SA kit was the product of Blue Gene company (Shang-
hai, China). Primary antibodies against Bcl-2 and Cas-
pase-3 were the products of Cell Signaling Technology,
Inc. (Boston, USA). Primary antibody against BNIP3
was purchased from R&D Systems China Co., Ltd.
(Shanghai, China). β-actin antibody was purchased
from Kangwei Century Biotech Co., Ltd. (Beijing, Chi-
na). Secondary antibody conjugated to horse radish
peroxidase was purchased from Beyotime institute of
Biotechnology (Beijing, China). Cell-culturing box for
CO2 at constant temperature was the product of Sanyo
Electric Co., Ltd. (Osaka, Japan). Microplate reader
was the product of Biotek Instruments, Inc. (Vermont,
USA). Flow cytometry was the product of Becton,
Dickinson and Company (New Jersey, USA). Electro-
phoresis and electroporation instrument was the prod-
uct of Bio-Rad Laboratories, Inc. (California, USA).
Cells culture
Human pancreatic cancer cells BxPC-3 were cultured
in DMEM medium and maintained in the incubator
at 37℃ with 5% CO2 in a humidified atmosphere.
The culture medium was replaced each two days and
the cells at logarithmic growth phase were used for the
following experiments.
Cell proliferation analysis
Human pancreatic cancer cells BxPC-3 were respective-
ly seeded in 96-well culture plates for different culture
period at 1×104 cells/well (24 h), 8×103 cells/well (48
h), 6×103 cells/well (72 h), 4×103 cells/well (96 h), 3×
103 cells/well (120 h). After overnight incubation, the
culture medium was replaced and JLC was added at fi-
nal concentrations in 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and
1.0 mg/mL, respectively. Blank control group (Bg, no
medium, no JLC), negative control group (Ng, no
JLC) and positive control group (GEM in 0.02 mg/
mL) were set up as well (six duplicates for each group).
After 24, 48, 72, 96, 120 h incubation, 10 μL
MTT (5 mg/mL) was added into each well at 37°C for
4 h. After the culture medium was removed, 150 μL
dimethylsulfoxide (DMSO) was added and shaken to
completely dissolve the formazan crystals. Optical den-
sity (OD) was measured at 570 nm with a microplate
reader. The percentage of inhibition was calculated as
the following formula: inhibition rate (IR)=[1-(ODSam-
ple-ODBg)/(ODNg-ODBg)] × 100% . The data were from
three independent replicates.
Assay of apoptosis by Annexin V-FITC/Propidium
iodide (AV-FITC/PI) staining
After 48 h incubation with JLC at 0.4, 0.6 and 0.8 mg/
mL, without JLC (negative control) or positive control
group (GEM in 0.02 mg/mL), supernatants were col-
lected and cells were digested. Cells were then mixed
with supernatants at 5×105 cells/group and centrifuged
at the speed of 1000 rpm for 5 min at 4℃ . Superna-
tants were discarded and cells were suspended in phos-
phate buffered solution (PBS). This procedure was re-
peated twice. Cells were then suspended in 500 μL
Binding Buffer. 5 μL AV-FITC and 10 μL PI were
added and incubated in dark place at room tempera-
ture for 5 min. Flow cytometry was used to detect the
living cells as well as early, moderate and late apoptotic
cells or necrotic cells.
Determine the change of cell cycle by PI staining
After 48 h incubation with JLC at 0.4, 0.6 and 0.8 or
without JLC (negative control), supernatants were col-
lected and cells were digested. Cells were then mixed
with supernatants at 1×106 cells/group and centrifuged
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at the speed of 1000 rpm for 5 min at 4℃ . Superna-
tant was discarded and 1 mL of PBS was added at
room temperature to resuspended cells. Resuspened
cells were then transferred gently to 4 mL of absolute
ethanol at -20℃ with high speed vortexing and then
kept at -20℃ for 10 min. The cells were pelleted by
centrifugation, and then the ethanol was discarded.
5 mL of PBS was added at room temperature to rehy-
drate cells for 15 min. The cell suspension was centri-
fuged and the supernatant was discarded. 1 mL of
DNA staining solution was added. Cells were incubat-
ed for 30 min at room temperature and analyzed by
flow cytometry.
Detect S100 Calcium binding protein A4 (S100A4)
in the cells matrix by ELISA
Supernatants collected from JLC treatment groups for
48 h (0.4, 0.6 and 0.8 mg/mL), or negative control
group were mixed with buffer solution at the ratio of
10∶1, and incubated for 1 h at room temperature.
50 μL of standards or samples were added to the re-
spective wells in the antibody pre-coated microtiter
plate (4 duplicate wells for each group). 100 μL of en-
zyme conjugate was added to each well and mixed
well. Plates were covered and incubated at 37℃ for 1
h. The microtiter plate was washed for five times. FiftyμL substrate A and 50 μL substrate B were added to
each well, and then incubated for 10 min in dark place
at 20℃-25℃ . 50 μL of stop solution was added to
each well and mixed well. The OD was read at 450 nm
using a microtiter plate reader within 30 min of final
incubation.
Detect expression level of proteins by western blotting
Cells collected from JLC treatment groups for 48 h
(0.4, 0.6 and 0.8 mg/mL), or negative control group
were lysed to extract proteins. The Bicinchoninic acid
method was used to detect the concentration of pro-
tein. The Sodium dodecyl sulfate (SDS) polyacryl-
amide gel electrophoresis was used to separate protein
(100 μg per hole). Protein was electrically transferred
to a polyvinylidene fluoride (PVDF) membrane. West-
ern blot assay was used to detect the expression level of
the Bcl-2, Caspase-3 and BNIP3. The PVDF mem-
brane was immersed in Tris-Buffered Saline and Tween
20 (TBST) containing 5% skimmed milk powder at
room temperature for 1 h to close. The corresponding
primary antibody was incubated at 4°C overnight. The
membrane was rinsed 3 times for 10 min each at room
temperature with slow agitation in the TBST. The
membrane was exposed for 2 h at room temperature to
secondary antibody conjugated to horse radish peroxi-
dase. After rinsing, the membrane was incubated in the
chemical luminescence liquid and exposed onto the
X-ray film in a dark room and fixed to observe targeted
protein.
Statistical analysis
All statistical analysis were undertaken by SPSS 19.0
(SPSS Inc., Chicago, USA). The data are expressed as
mean±standard deviation (SD). LSD-t and Welch test
was used. In all the test, P<0.05 was regarded as a sta-
tistically significant difference.
RESULTS
JLC inhibited the proliferation of human pancreatic
cancer cells BxPC-3
The MTT assay was used to determine the effect of
JLC on the proliferation of human pancreatic cancer
cells BxPC-3. Table 1 and Figure 1 illustrated the inhi-
bition rate of 0.05-1.00 mg/mL JLC and GEM
(0.02 mg/mL) on the growth of human pancreatic can-
cer cells BxPC-3 after 24-120 h of incubation. The re-
sults showed that JLC inhibited the proliferation of hu-
man pancreatic cancer cells BxPC-3 in dose-dependent
and time-dependent manner, and GEM inhibited the
Table 1 The inhibition rate of proliferation of human pancreatic cancer cells BxPC-3 affected by JLC (%, xˉ ± s , n=6)
Notes: JLC: Jinlong capsule; BxPC-3: pancreatic cancer cells. Compared with the negative control group, aP<0.05; compared with
the positive control group, bP<0.05.
Group
Negative control
JLC (0.05 mg/mL)
JLC (0.1 mg/mL)
JLC (0.2 mg/mL)
JLC (0.4 mg/mL)
JLC (0.6 mg/mL)
JLC (0.8 mg/mL)
JLC (1.0 mg/mL)
GEM (0.02 mg/mL)
24 h
0
-1.0±7.3b
-16.9±15.8ab
-13.1±12.4ab
-8.0±6.1b
1.8±8.1b
19.2±9.3ab
45.2±6.2a
47.1±5.4a
48 h
0
0.6±10.7b
-3.9±21.0b
-4.6±11.0b
14.4±11.7ab
33.2±7.4ab
53.3±5.4a
83.3±2.3ab
61.8±5.6a
72 h
0
-2.1±6.0b
-9.5±9.2ab
6.8±6.5b
33.4±12.1ab
65.1±5.8ab
92.0±5.1ab
96.6±1.8ab
80.4±2.4a
96 h
0
6.1±20.5b
-6.2±16.3b
9.1±16.8b
44.8±13.3ab
77.2±7.3a
94.8±2.5a
98.4±1.5a
88.1±1.3a
120 h
0
3.6±20.6b
-1.4±23.6b
28.4±24.8ab
68.8±10.4ab
91.0±5.8a
99.4±1.6a
99.4±1.0a
93.8±2.0a
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proliferation of the cells in a time-dependent manner.
However, after 48 h incubation, when compared to the
negative control group, while JLC still showed robust
effects on cell growth suppress at the concentrations of
0.4, 0.6, 0.8, 1.0 mg/mL [(14.38 ± 11.68)% to (83.33
± 2.29)% inhibition] (all P<0.05), and the inhibition
was not significantly different between the group of
0.8 mg/mL and the positive control group (P>0.05),
and the 1.0 mg/mL dose group performed even better
than the positive drug group (P<0.05). In addition, af-
ter incubation for 48 h, cell metabolite rate was rela-
tively low which has less impact on the results. Based
on these facts, the follow-up experiments were per-
formed with JLC at the dose of 0.4, 0.6, 0.8 mg/mL
and the incubation time were set at 48 h.
JLC promoted the apoptosis of human pancreatic
cancer cells BxPC-3
Annexin V-FITC/PI double dyed flow cytometry was
used to detect the apoptosis of human pancreatic can-
cer cells BxPC-3 with the treatment of JLC. As shown
in Figure 2, after 48 h treatment, the apoptotic cells in
the negative control group was (7.1±3.2)%, and JLC at
the dose of 0.4, 0.6 and 0.8 mg/mL promoted the
apoptosis by (13.6 ±3.4)% , (27.0 ±2.1)% and (31.0 ±
3.5)% (all P<0.05), and there was no variance between
the group of 0.8 mg/mL and the positive control (P>
0.05). The data suggested JLC could significantly pro-
mote apoptosis of human pancreatic cancer cells Bx-
Figure 3 The cell cycle of human pancreatic cancer cells Bx-
PC-3 in different culture media
JLC: Jinlong capsule. Compared with the negative control
group, aP<0.05.
a
a
a
a
aa
aa a
Figure 2 Apoptosis of human pancreatic cancer cells BxPC-3
in different culture media
JLC: Jinlong capsule; GEM: gemcitabine hydrochloride. Com-
pared with the negative control group, aP<0.05.
a
a
aa
Figure 1 Inhibition rate of proliferation of human pancreatic cancer cells BxPC-3 affected by JLC
IR: inhibition rate; JLC: Jinlong capsule; GEM: gemcitabine hydrochloride.
Table 2 The OD values of cell matrix in different groups and the concentration of S100A4 (n=4)
Group
OD
Mean
Concentration (pg/mL)
JLC (0.8 mg/mL)
0.126
0.124
0.13
0.124
0.1260±0.0028a
16.782
JLC (0.6 mg/mL)
0.129
0.127
0.131
0.129
0.1290±0.0016a
17.907
JLC (0.4 mg/mL)
0.132
0.13
0.126
0.129
0.1293±0.0025a
17.982
Negative control
0.137
0.133
0.136
0.131
0.1343±0.0028
19.789
Notes: OD: optical density; JLC: Jinlong capsule. Compared with the negative control group, aP<0.05.
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PC-3 in a dose-dependent manner. With elevated con-
centrations of JLC, number of late apoptotic cells in-
creased more apparently.
JLC affected the cell cycle of human pancreatic
cancer cells BxPC-3
PI-stained flow cytometry was used to detect the
change of cell cycle of human pancreatic cancer cells
BxPC-3 treated with JLC. As shown in Figure 3, after
48 h treatment, the number of cells in phase G0/G1, S
and G2/M were all significantly different between the
negative control and the JLC treatment group at the
dose of 0.4, 0.6 and 0.8 mg/mL (all P<0.05). Number
of cells in S and G2/M phase increased significantly
with JLC treatment while the number of cells in G1/G0
phase reduced. The results illustrated that JLC affected
the circulation of normal cell cycle by arresting cells at
the G2/M and S phase, thus inhibiting the cell prolifer-
ation.
JLC affected the expression of S100A4 in the cells
matrix
ELISA was used to detect the change of S100A4 in the
cells matrix of human pancreatic cancer cells BxPC-3
treated with JLC. As shown in Table 2, after 48 h incu-
bation, the OD values of cell matrix in the groups of
JLC in the concentrations of 0.4, 0.6 and 0.8 mg/mL
were totally different as compared with the negative
control (all P<0.05). The levels of S100A4 in the
groups treated with 0.4, 0.6, 0.8 mg/mL JLC and
negative control were 17.982, 17.907, 16.782 and
19.789 pg/mL respectively. The results illustrated that
JLC reduced the expression of S100A4 in the human
pancreatic cancer cells BxPC-3.
JLC affected the expression level of apoptosis-related
proteins
Western blot analysis was used to detect the expression
level of proteins of Bcl-2, Caspase-3 and BNIP3. As
shown in Figure 4, after 48 h incubation, compared
with the negative control, the expression level of Bcl-2
in JLC treatment group decreased, and the expression
of BNIP3 increased in a dose-dependent manner. How-
ever, the expression of Caspase-3 was not significantly
changed in each group. The results illustrated that JLC
promotes the apoptosis of human pancreatic cancer
cells BxPC-3 by both increasing the expression of
pro-apoptotic protein BNIP3 and reducing the level of
anti-apoptotic protein Bcl-2.
DISCUSSION
In multicellular organisms, cell death has two different
forms, namely necrosis and apoptosis. Apoptosis is the
process of dying in physiological or pathological condi-
tions under control by the gene, known as pro-
grammed cell death, and is a hot research topic of anti-
tumor. In this study, the result of Annexin-VFITC/PI
double staining flow cytometry showed that the JLC
can promote apoptosis of human pancreatic cancer
cells BxPC-3 in a significant dose-dependent manner
which was consistent with the MTT assay and illustrat-
ed that promoting apoptosis may be one of the mecha-
nisms involved in the suppression of human pancreatic
cancer cells BxPC-3 proliferation by JLC. Further-
more, JLC affected the cell division cycle by arresting
cells at the S and G2/M phase which also contributed
to the inhibition of cell proliferation.
S100A4 is a protein that has multiple functions, includ-
ing enhancing the proliferation of tumor cell, inhibit-
ing cell apoptosis, promoting cell motility, reducing
cell adhesion, promoting angiogenesis as well as trigger-
ing cells invasion and metastasis.6-8 It is closely related
to the generation and development of tumor. S100A4
presents in the cell as a non-covalently bound dimer,
and is secreted into the cell matrix as covalent dimer.
S100A4 protein in the cell matrix is the basis of signal
transduction between cells and plays a major role in
mediating cell and cell matrix interaction.9 As shown
in the result of ELISA assay, S100A4 in the cell matrix
decreased when the human pancreatic cancer cells Bx-
PC-3 were treated with JLC. A large number of studies
have confirmed that the downregulation of S100A4 in-
hibited the proliferation, migration and invasion of
pancreatic cancer cell.10 Therefore, lower S100A4 level
in the cell matrix with JLC treatment may also contrib-
ute to the inhibition effects of JLC on the proliferation
of human pancreatic cancer cells BxPC-3.
The molecular mechanism of apoptosis is very compli-
cated, influenced by many factors, and involves the par-
ticipation of a variety of apoptosis-related proteins, in-
cluding pro-apoptosis proteins and anti-apoptosis pro-
teins. Bcl-2 protein, as an anti-apoptotic protein, can
prolong cell survival and inhibit cell apoptosis.11 In this
study, Western blot results showed that the JLC could
reduce the expression of Bcl-2 protein when in Bx-
PC-3 human pancreatic cancer cells and may contribute
to the cells apoptosis.
Caspase-3
β-action
BNIP3
Bcl-2
A B C D
Figure 4 The expression of protein β-action, Caspase-3,
BNIP3 and Bcl-2
A: JLC (0.8 mg/mL); B: JLC (0.6 mg/mL); C: JLC (0.4 mg/mL);
D: negative control. JLC: Jinlong capusle; BNIP3: BCL2/ade-
novirus E1B 19 kDa protein-interacting protein 3.
kDa
43
35
30
28
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BNIP3, as a pro-apoptotic protein, can antagonize the
anti-apoptotic function of Bcl-2 and Bcl-xl through the
formation of isomers with the Bcl-2 and Bcl-xl.12 BNIP3
also enhances the pro-apoptotic function of Bax and
Bak, and induces autophagy.13 Under the normal circum-
stances, BNIP3 protein is not expressed in human pan-
creatic cancer cell lines BxPC-3.14 The previous studies
showed that the over-expression of S100A4 is one of the
mechanisms related to the reduced expression of BNIP3
in pancreatic cancer.15 Western Blot results showed that
the JLC can promote the expression of BNIP3 protein in
a dose-dependent manner in human pancreatic cancer
cells BxPC-3. ELISA results showed that the JLC can re-
duce expression of S100A4 dose-dependently in human
pancreatic cancer cells BxPC-3. In summary, JLCmay in-
crease the expression of pro-apoptotic protein BNIP3 by
reducing the expression of S100A4 protein in the cell ma-
trix. These two factors mutually affected, synergistically
promoting the apoptosis of BxPC-3 human pancreatic
cancer cells.
Caspase-3 is in the downstream of cell apoptosis, in-
volved in apoptosis execution.16 The result of Western
blot showed that the expression of Caspase-3 protein had
no significant difference between each group. Therefore,
we postulate the pathway of apoptosis of human pancre-
atic cancer cells BxPC-3 triggered by JLC was not
throughCaspase-3 protein.
In summary, this study demonstrated that JLC can inhib-
it the proliferation of human pancreatic cancer cells Bx-
PC-3 through the promotion of apoptosis, arresting the
cell division cycle at S and G2/M phase and reducing the
expression of S100A4 protein. The mechanism of pro-
moting apoptosis may be associated with raising
pro-apoptosis protein BNIP3 and reducing the an-
ti-apoptosis protein Bcl-2. We believe this study only re-
veals part of the molecular mechanisms involved in JLC's
anti-tumor effects andwarrants further in-depth study.
The theory of Traditional Chinese Medicine holds that
the formation of tumors is closely related with blood sta-
sis, phlegm stagnation andQi stagnation. JLC composed
by Xianbaihuashe (Fresh Bungarus), Xianjinshe (Fresh
Agkistrodon), Xianshougong (Fresh Gecko), etc. has the
function of promoting blood circulation, resolving mass-
es and stagnation, and dredging collaterals,17,18 so it has
good anti-tumor function. In this study, the results
showed that JLC inhibited the proliferation of human
pancreatic cancer cells BxPC-3, consistenting with the
relevant Chinese medicine theory. In additon, this study
revealed that JLC as a compound preparation, holds the
multi-targeted therapeutic effects of traditional Chinese
medicine.
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